5,411 Shares in Axon Enterprise, Inc (NASDAQ:AXON) Acquired by Bosman Wealth Management LLC

Bosman Wealth Management LLC bought a new position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 5,411 shares of the biotechnology company's stock, valued at approximately $2,846,000. Axon Enterprise makes up about 2.9% of Bosman Wealth Management LLC's portfolio, making the stock its 15th largest holding.

Several other large investors also recently added to or reduced their stakes in AXON. Fourth Dimension Wealth LLC bought a new stake in Axon Enterprise during the fourth quarter valued at about $30,000. Bartlett & CO. Wealth Management LLC increased its stake in shares of Axon Enterprise by 132.0% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 33 shares during the period. Catalyst Capital Advisors LLC bought a new position in shares of Axon Enterprise in the first quarter worth about $32,000. Alpine Bank Wealth Management bought a new position in shares of Axon Enterprise in the first quarter worth about $40,000. Finally, Elequin Capital LP bought a new position in shares of Axon Enterprise in the fourth quarter worth about $46,000. 79.08% of the stock is owned by institutional investors.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, President Joshua Isner sold 905 shares of the firm's stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $776.39, for a total value of $702,632.95. Following the completion of the sale, the president owned 268,735 shares in the company, valued at approximately $208,643,166.65. This trade represents a 0.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Jennifer H. Mak sold 75 shares of the firm's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $771.81, for a total transaction of $57,885.75. Following the completion of the sale, the chief accounting officer owned 15,240 shares of the company's stock, valued at $11,762,384.40. The trade was a 0.49% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,642 shares of company stock worth $30,500,428. Corporate insiders own 4.40% of the company's stock.

Axon Enterprise Price Performance

AXON stock traded down $3.37 during trading on Friday, hitting $729.62. 1,120,957 shares of the stock traded hands, compared to its average volume of 545,551. Axon Enterprise, Inc has a one year low of $279.02 and a one year high of $830.21. The stock has a market cap of $56.80 billion, a price-to-earnings ratio of 176.24, a P/E/G ratio of 83.99 and a beta of 1.29. The company has a 50 day simple moving average of $752.67 and a 200 day simple moving average of $641.02. The company has a current ratio of 2.83, a quick ratio of 2.62 and a debt-to-equity ratio of 0.68.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.07. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The firm had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. During the same period last year, the firm posted $1.15 EPS. The firm's quarterly revenue was up 31.3% on a year-over-year basis. Equities analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Barclays lifted their price objective on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Wolfe Research assumed coverage on shares of Axon Enterprise in a report on Monday, July 7th. They issued an "outperform" rating for the company. Bank of America increased their price target on shares of Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a report on Wednesday, June 4th. Needham & Company LLC increased their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Finally, The Goldman Sachs Group increased their price target on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company's stock. According to MarketBeat, Axon Enterprise has an average rating of "Moderate Buy" and a consensus target price of $699.55.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.